In this cohort study of 354 294 US veterans with migraine disorder (8 178 652 person-trials), CGRP mAb treatment was not associated with a significant increase or reduction in risk of SARS-CoV-2 infection, hospitalization, requiring supplemental oxygen, use of mechanical ventilation, or death. The gene discussed is CALCA; the disease is migraine disorder.